Literature DB >> 3062267

Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor.

A von Herbay1, B Dörken, G Mall, M Körbling.   

Abstract

The myocardium was studied histologically at autopsy in seven patients who died 9-85 days (median 22 days) after autologous bone marrow or blood-derived stem-cell transplantation. Clinical investigations including echocardiography suggested normal cardiac function in all patients prior to transplantation. Myeloablation was performed by total body irradiation (1200-1560 cGy) and cyclophosphamide (200 mg/kg). Morphological findings were graded semi-quantitatively and correlated with previous and current therapy. Histological alterations did not correspond to the dosages of myeloablative therapy. However, cardiac failure, the primary cause of death in four patients, was associated with coagulative fiber necroses and contraction band necroses, which may be related to acute cyclophosphamide toxicity. In three of these patients high-dose cardiotoxic pretreatment with anthracyclines and mitoxantrone has been performed beyond the critical cardiotoxic level. High-dose pretreatment was correlated with histological hallmarks of anthracycline heart disease: marked chromatin clumping of myocardial cell nuclei (3/3 patients), occurrence of plurivesicular "adria" cells (3/3 patients), and diffuse interstitial myocardial fibrosis (2/3 patients). Our morphological observations indicate for the first time that pretreatment with anthracyclines and mitoxantrone may enhance cardiotoxicity of myeloablative therapy in bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062267     DOI: 10.1007/bf01727665

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  32 in total

1.  Hyperfractionated total body irradiation as part of autologous bone marrow transplantation.

Authors:  D Fehrentz; M Körbling; U Weischedel
Journal:  Strahlenther Onkol       Date:  1986-04       Impact factor: 3.621

2.  Toxicity of high dose Ara-C in children and adolescents.

Authors:  N J Barrios; C K Tebbi; A I Freeman; M L Brecher
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

3.  Nonbacterial thrombotic endocarditis in bone marrow transplant patients.

Authors:  R A Patchell; C L White; A W Clark; W E Beschorner; G W Santos
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860

Review 4.  Radiation-induced heart disease: an update.

Authors:  J R Stewart; L F Fajardo
Journal:  Prog Cardiovasc Dis       Date:  1984 Nov-Dec       Impact factor: 8.194

5.  Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity.

Authors:  F Appelbaum; J A Strauchen; R G Graw; D D Savage; K M Kent; V J Ferrans; G P Herzig
Journal:  Lancet       Date:  1976-01-10       Impact factor: 79.321

6.  Interstitial pneumonitis following autologous bone marrow transplantation.

Authors:  R Pecego; R Hill; F R Appelbaum; D Amos; C D Buckner; A Fefer; E D Thomas
Journal:  Transplantation       Date:  1986-11       Impact factor: 4.939

7.  Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy.

Authors:  J M Isner; V J Ferrans; S R Cohen; B G Witkind; R Virmani; J S Gottdiener; J R Beck; W C Roberts
Journal:  Am J Cardiol       Date:  1983-04       Impact factor: 2.778

8.  Differentiating characteristics of myocardial nuclei in cardiomyopathy.

Authors:  B J Unverferth; C V Leier; R D Magorien; D V Unverferth
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

9.  Anthracycline cardiomyopathy monitored by morphologic changes.

Authors:  M E Billingham; J W Mason; M R Bristow; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

10.  Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation.

Authors:  F L Dulley; E J Kanfer; F R Appelbaum; D Amos; R S Hill; C D Buckner; H M Shulman; G B McDonald; E D Thomas
Journal:  Transplantation       Date:  1987-06       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.